Therna and Charles River Partner on RNA Therapeutics
Therna Biosciences and Charles River have announced a collaboration to advance single-patient, programmable RNA therapeutics for ultra-rare diseases. The partnership highlights the need for engineers who can build flexible, compliant data pipelines that bridge ML and wet-lab workflows.
This collaboration aims to address the significant challenges in developing drugs for rare and ultra-rare diseases, which include small, geographically dispersed patient populations and a limited understanding of disease progression. The partnership will initially focus on two single-patient cases: an adult with a rare, progressive lung fibrosis and a newborn with the ultra-rare central nervous system disorder, Lamb-Shaffer Syndrome. Therna Biosciences, a San Francisco-based startup founded in 2023, brings its generative AI platform to the table. This platform integrates RNA biology with machine learning to design and optimize programmable RNA therapeutics, such as messenger RNA (mRNA) and antisense oligonucleotides (ASOs). For the lung fibrosis patient, Therna's AI platform generated a therapeutic mRNA candidate in just three days, with lab validation completed in under three months. Charles River Laboratories, a major contract research organization (CRO), will leverage its extensive experience in preclinical development to advance these novel therapies. The company will conduct the necessary testing to move the treatments toward single-patient Investigational New Drug (IND) applications, a critical regulatory step for clinical trials. Charles River has been actively expanding its capabilities in cell and gene therapy through various partnerships and acquisitions. The partnership highlights a critical need for engineers who can architect and manage complex data pipelines that bridge computational and biological workflows. Building these "AI-ready" systems requires expertise in cloud infrastructure (like AWS or Azure), MLOps tools for model versioning and deployment (like MLflow), and workflow orchestrators (like Kubeflow or Nextflow). The goal is to create reproducible, secure, and compliant pipelines that can handle large-scale genomic and experimental data. This "lab-in-the-loop" approach, where AI models propose RNA sequences that are then experimentally validated, with the results feeding back to improve the models, is becoming a paradigm shift in drug development. The ultimate aim is to accelerate the design-to-clinic timeline for therapies that are precisely tailored to an individual's genetic makeup. This is particularly crucial for ultra-rare diseases where traditional drug development is often not financially viable.
